Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide

Chest

Volumn 127, Issue 5, 2005, Pages 1647-1653

  Lepore, John J ^a,b   Maroo, Anjli ^a   Bigatello, Luca M ^a   Dec, G William ^a   Zapol, Warren M ^a   Block, Kenneth D ^a   Semigran, Marc J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Congestive; Heart failure; Hypertension; Nitric oxide; Pulmonary; Type 5 phosphodiesterase; Vasodilator agents

Indexed keywords

NITRIC OXIDE; SILDENAFIL; BRONCHODILATING AGENT; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HUMAN; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE; DRUG COMBINATION; HEART OUTPUT; HEMODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY ARTERY;

ADULT; BRONCHODILATOR AGENTS; CARDIAC OUTPUT; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY ARTERY; VASODILATOR AGENTS;

EID: 19844361803     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.5.1647     Document Type: Article

References (22)

1. Di Salvo TG, Mathier M, Semigran MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25:1143-1153
2. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000; 102:1718-1723
3. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1- mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732-736
4. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000; 101:2922-2927
5. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999; 91:1090-1121
6. Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90:2780-2785
7. Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994; 24:982-988
8. Kieler-Jensen N, Ricksten SE, Stenqvist O, et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 1994; 13:366-375
9. Koelling TM, Kirmse M, Di Salvo TG, et al. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998; 81:1494-1497
10. Ichinose F, Adrie C, Hurford WE, et al. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998; 88:410-416
11. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92:1702-1712
12. Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90:677-680
13. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105:2398-2403
14. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104:424-428
15. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895-900
16. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91:307-310
17. Grossman W. Evaluation of systolic and diastolic function of the ventricles and myocardium. In: Baim DS, Grossman W, eds. Grossman's cardiac catheterization, angiography, and intervention. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2000; 367-392
18. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106:1097-1103
19. Hare JM, Shernan SK, Body SC, et al. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance. Circulation 1997; 95:2250-2253
20. Cockrill BA, Kacmarek RM, Fifer MA, et al. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001; 119:128-136
21. Senzaki H, Smith CJ, Juang GJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001; 15:1718-1726
22. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83:3C-12C